Importantly, a 2012 study showed that while conventional immunohistochemistry analysis showed HER2 overexpression in only 29% of evaluated tumor sites, using more sensitive methods emphasized that all human ovarian cancers express immunologically-detectable HER2 levels [11], highlighting the potential of HER2 as a targetable biomarker. This evidence concerns the gene ERBB2 and ovarian cancer.